和黄医药(0013.HK):公司实现盈利 全球创新管线持续催化

平安证券
24 Mar

事项:3 月20 日,和黄医药公布2024 年年报,公司总收入6.30 亿美元(-24.8%),,主要受2023 年同期呋喹替尼首付款高基数影响,公司归母净利润为0.38 亿美元,实现盈利,基本符合预期。平安观点:核心产品销售额保持较快增长,呋喹替尼海外快速放量。公司肿瘤业务24 年全年收入3.63 亿美元。其中,肿瘤产品收入2.715 亿美元(2023年:1.64 亿美元),增长受武田海外市场...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10